Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2024) 144 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2024-208684

Published: 2024

Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood (2024) 144 (Supplement 1): 446.

https://doi.org/10.1182/blood-2024-203938

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Jennifer Marvin-Peek, Hagop M. Kantarjian, Wei-Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti, Nicholas J. Short, Steven M. Kornblau, Naveen Pemmaraju, Eitan Kugler, Alexandre Bazinet, Yesid Alvarado-Valero, Hussein A. Abbas, Guillermo Garcia-Manero, Uday Popat, Elizabeth J. Shpall, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2024-202414

Published: 2024

Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Thomas Mathew, Koji Sasaki, Yesid Alvarado Valero, Danielle Hammond, Fadi G. Haddad, William G. Wierda, Alessandra Ferrajoli

Blood (2024) 144 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2024-198701

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2024-204040

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood (2024) 144 (Supplement 1): 216.

https://doi.org/10.1182/blood-2024-204375

Published: 2024

Journal Articles

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood (2024) 144 (Supplement 1): 6126.

https://doi.org/10.1182/blood-2024-207413

Published: 2024

Journal Articles

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

Blood (2024) 144 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2024-210642

Published: 2024

Journal Articles

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Wanda Lopez, Ghayas C. Issa, Musa Yilmaz, Mahesh Swaminathan, Jo Ishizawa, Alexandre Bazinet, Yesid Alvarado Valero, Nitin Jain, William G. Wierda, Alessandra Ferrajoli

Blood (2024) 144 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2024-200331

Published: 2024

Journal Articles

Cellular and Molecular Effects of Suspending Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia in Sustained Partial Remission

Marzia Palma, Maria Lisa Andersson, Tom Adriaan Mulder, Kia Heimersson, Anna Berglöf, Lucia Peña Perez, Teresa Del Peso Santos, Yesid Alvarado Valero, Rula Zain-Luqman, Robert Månsson, Richard Rosenquist, Edvard C.I. Smith, Anders Österborg, Jeanette Lundin

Blood (2024) 144 (Supplement 1): 6756.

https://doi.org/10.1182/blood-2024-198001

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2024-205186

Published: 2024

Journal Articles

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Jennifer Marvin-Peek, Courtney D. DiNardo, Wei-Ying Jen, Nicholas J. Short, Yesid Alvarado Valero, Gautam Borthakur, Naval Daver, Eitan Kugler, Alexandre Bazinet, Hussein A. Abbas, Musa Yilmaz, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2024-202405

Published: 2024

Journal Articles

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 734.

https://doi.org/10.1182/blood-2024-203459

Published: 2024

Journal Articles

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Blood (2024) 144 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2024-200387

Published: 2024

Journal Articles

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede Begna, Sameem Abedin, MHD Monzr M. Al Malki, Vijaya Raj Bhatt, Nathalie Javidi-Sharifi, Prabhu Rajagopolan, Sandra Wiley, Richard G Ghalie, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2024-198718

Published: 2024

Journal Articles

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2024) 144 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2024-207962

Published: 2024

Journal Articles

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2024-198541

Published: 2024

NARROW

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Cellular and Molecular Effects of Suspending Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia in Sustained Partial Remission

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only